Cargando…
Directions and Challenges in Smoking Cessation Treatment
Raising the tax on tobacco-related products is the most effective and sustainable intervention for smoking cessation. The 2015 tobacco-tax increase resulted in a decreased smoking rate among Korean adult men. However, participation in the government-sponsored smoking-cessation programs developed aft...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837376/ https://www.ncbi.nlm.nih.gov/pubmed/33261242 http://dx.doi.org/10.4046/trd.2020.0150 |
_version_ | 1783642947738140672 |
---|---|
author | Kim, Jae Yeol |
author_facet | Kim, Jae Yeol |
author_sort | Kim, Jae Yeol |
collection | PubMed |
description | Raising the tax on tobacco-related products is the most effective and sustainable intervention for smoking cessation. The 2015 tobacco-tax increase resulted in a decreased smoking rate among Korean adult men. However, participation in the government-sponsored smoking-cessation programs developed after the 2015 tobacco tax increase has declined sharply since 2018. The popularity of electronic cigarettes (e-cigarettes) seems to be an important factor in this decline. Indeed, the market share of e-cigarettes has increased steadily since 2007, when the e-cigarette was introduced in Korea as a vaporizer. The introduction of the tobacco-heating device IQOS in 2017 resulted in the skyrocketing popularity of e-cigarettes, especially among the young generation of Koreans. The U.S. Food and Drug Administration (FDA) authorized marketing of IQOS as a “reduced exposure” tobacco product on July 7, 2020, further complicating smoking-cessation efforts. The agency announced that IQOS produces fewer or lower levels of some toxins than combustible cigarettes. However, FDA authorization does not mean that these products are safe. There is no evidence that reducing the harmful chemical components leads to health benefits. Clinicians need to maintain the position that those who smoke, regardless of tobacco-product type, should be counseled for smoking cessation and prescribed appropriate proven pharmacologic agents. |
format | Online Article Text |
id | pubmed-7837376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
record_format | MEDLINE/PubMed |
spelling | pubmed-78373762021-02-01 Directions and Challenges in Smoking Cessation Treatment Kim, Jae Yeol Tuberc Respir Dis (Seoul) Review Article Raising the tax on tobacco-related products is the most effective and sustainable intervention for smoking cessation. The 2015 tobacco-tax increase resulted in a decreased smoking rate among Korean adult men. However, participation in the government-sponsored smoking-cessation programs developed after the 2015 tobacco tax increase has declined sharply since 2018. The popularity of electronic cigarettes (e-cigarettes) seems to be an important factor in this decline. Indeed, the market share of e-cigarettes has increased steadily since 2007, when the e-cigarette was introduced in Korea as a vaporizer. The introduction of the tobacco-heating device IQOS in 2017 resulted in the skyrocketing popularity of e-cigarettes, especially among the young generation of Koreans. The U.S. Food and Drug Administration (FDA) authorized marketing of IQOS as a “reduced exposure” tobacco product on July 7, 2020, further complicating smoking-cessation efforts. The agency announced that IQOS produces fewer or lower levels of some toxins than combustible cigarettes. However, FDA authorization does not mean that these products are safe. There is no evidence that reducing the harmful chemical components leads to health benefits. Clinicians need to maintain the position that those who smoke, regardless of tobacco-product type, should be counseled for smoking cessation and prescribed appropriate proven pharmacologic agents. The Korean Academy of Tuberculosis and Respiratory Diseases 2020-12 2020-12-02 /pmc/articles/PMC7837376/ /pubmed/33261242 http://dx.doi.org/10.4046/trd.2020.0150 Text en Copyright © 2020 The Korean Academy of Tuberculosis and Respiratory Diseases It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Review Article Kim, Jae Yeol Directions and Challenges in Smoking Cessation Treatment |
title | Directions and Challenges in Smoking Cessation Treatment |
title_full | Directions and Challenges in Smoking Cessation Treatment |
title_fullStr | Directions and Challenges in Smoking Cessation Treatment |
title_full_unstemmed | Directions and Challenges in Smoking Cessation Treatment |
title_short | Directions and Challenges in Smoking Cessation Treatment |
title_sort | directions and challenges in smoking cessation treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837376/ https://www.ncbi.nlm.nih.gov/pubmed/33261242 http://dx.doi.org/10.4046/trd.2020.0150 |
work_keys_str_mv | AT kimjaeyeol directionsandchallengesinsmokingcessationtreatment |